#U.S. Compounding Pharmacies | Explore Tumblr Posts and Blogs

priyanshisingh · 1 year

Text

U.S. 503b Compounding Pharmacies Market - Future Growth Prospects for the Global Leaders

The latest market report published by Credence Research, Inc. “Global U.S. 503b Compounding Pharmacies Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028. The U.S. 503b compounding pharmacies market is anticipated to grow at a substantial CAGR of 7.80% in the upcoming years. The U.S. 503b compounding pharmacies industry was estimated to be worth USD 1.1 billion in 2022 and was expected to be worth USD 1.9 billion by 2030.

One of the major segments in the market is the phenylephrine segment, which accounted for the largest market share in 2022. Phenylephrine is widely used to relieve nasal discomfort and has contributed to the segment's dominance. Another prominent segment is prefilled syringes, which are anticipated to hold a significant share in the market. The growing demand for easy-to-use drug delivery devices and healthcare professionals' efforts to reduce hospital errors are driving the demand for prefilled syringes.

U.S. 503b Compounding Pharmacies Market Growth Factor Worldwide is currently one of the most significant drivers of growth in the pharmaceutical industry worldwide. With an increasing demand for personalized medication, compounded drugs have become a popular choice among patients and healthcare providers alike. These pharmacies are regulated by the FDA and operate under strict guidelines to ensure that they provide safe, high-quality products to their customers. The U.S. 503b compounding pharmacies market has witnessed substantial growth in recent years due to factors such as advancements in technology, rising awareness about customized medications, and the need for cost-effective solutions for chronic illnesses. Additionally, favorable government regulations regarding compounding practices have also contributed significantly to the expansion of this market globally.

The COVID-19 pandemic has impacted the U.S. 503b Compounding Pharmacies market, with pharmacy staff struggling to meet the demand for medicines. In such times, 503B outsourcing facilities have played a crucial role in addressing drug scarcity and supplying critical care medicines to hospitals when commercial manufacturers cannot meet the demand.

The competitive landscape of the U.S. 503b Compounding Pharmacies market is highly dynamic, with key players focusing on expanding their market presence through mergers and acquisitions, collaborations, and strategic investments. Major companies in the market include Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, and Fagron Compounding Pharmacies, among others.

The report also highlights the regulatory landscape, with FDA authorizing 503A pharmacies to provide sterile medicines under patient-specific conditions. Additionally, the report provides insights into major investment activities and future plans of key players in the market.

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global U.S. 503b Compounding Pharmacies Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

In-depth analysis of the global market segmentation on the End-User and Application

Major nations in each region with their import/export statistics

The global U.S. 503b Compounding Pharmacies Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Full Report: https://www.credenceresearch.com/report/u-s-503b-compounding-pharmacies-market

Visit: https://www.credenceresearch.com/

Related Report: https://www.credenceresearch.com/report/anti-inflammatory-drugs-market

Related Report: https://www.credenceresearch.com/report/cannabis-concentrate-market

Browse Our Blog: https://www.linkedin.com/pulse/us-503b-compounding-pharmacies-market-future-growth-priyanshi-singh

#U.S. 503b Compounding Pharmacies Market

1 note · View note

researchprecedence45 · 2 years

Link

According to Nova one advisor's latest report, titled U.S. Compounding Pharmacies Market Size: Industry Trends, Share, Growth, Opportunity and Forecast 2022-2030," the U.S. Compounding Pharmacies market reached a value of US$ 5.17 Billion in 2021. Looking forward, Nova one advisor expects the market to reach a value of US$ 8.3 Billion by 2030, exhibiting a CAGR of 5.41% during 2022-2030.

#U.S. Compounding Pharmacies Market Size

0 notes

mrunalnerkarblog · 2 years

Link

The process of combining, mixing, or changing substances to create a treatment according to the needs of a specific patient is known as drug compounding. Compounding is the process of mixing two or more medications. Individual chemicals are blended in the exact strength and dosage form required for the patient. Compounded drugs are prepared based on a practitioner's request.

#U.S. Ophthalmic Compounding Pharmacies Market

0 notes

jesse-pinkman123 · 2 years

Link

The U.S. Compounding Pharmacies Industry sector is the focus of U.S. Compounding Pharmacies Market Research. The current industry scenario was examined, as well as future industry projections. The market research report evaluates a variety of relevant aspects

#U.S. Compounding Pharmacies Market Research #U.S. Compounding Pharmacies Market Growth

0 notes

whilomm · 18 days

Text

hey question bc its been a few years since ive looked into it and idk if its still pretty hard nowadays, anyone here got experience using topical DHT for bottom growth in the U.S.? i remember last time i looked it up it was kinda in like. a legal grey area where u could import from this one place and it was kiiinda illegal, or there was shit about compounding pharmacies which werent illegal but there were some hoops to jump thru, but google is kinda sucking ass atm so. anyone got any good recent info on it?

im trying to look up more info on it but most im finding is either over a decade old, or pretty vague on the details (mentioning oh you CAN import it but we cant give you the details so look it up wink wink nudge nudge, but google FUCKING SUCKS now so its not showing me Whatever It Meant). having to wade thru a lotta results that are either medical studies (which, interesting but not what im looking for) or stuff about dht BLOCKERS which. opposite of what i want yeah.

anyway questions i have are like, what the actual process of getting ahold of it looks like (including "how hard is it to convince a doctor to prescribe shit in other peoples experience" and "how expensive is this shit") and on what level of legality it is atm (bc again im finding super out of date articles)

#buzzy #trans #transmasc #trans men #testosterone #dht #google is being Somewhat Unhelpful #if anyone has like any more RECENT articles/guides to link that would be helpful

13 notes · View notes

brostateexam · 1 year

Text

It turns out she’s down about ten pounds and happy about it. “Somebody once told me I had a size-zero personality, and they assumed that I was thinner than I was,” she tells me. “We don’t talk about it, but everybody knows it. Thin is power.”

Allison isn’t alone in seeming to be suddenly, unaccountably slimmer of late. She admitted to me — with the provision that I not use her real name — the reason, one that is increasingly common if still not quite openly discussed. For the past month, she’s been jabbing herself every week with Ozempic, the heavily advertised (“Oh, oh, oh, Ozempic,” to the tune, none too subtly, of the ’70s classic-rock hit “Magic”) diabetes miracle drug, which works by mimicking a naturally occurring hormone, GLP-1 (glucagon-like peptide one), to manage hunger and slow stomach emptying.

For diabetics, it lowers blood-sugar levels. It also subdues the imp of appetite. The pounds fly off. That’s why Allison, who is not diabetic, prediabetic, or even overweight, is on it. Doctors have wide latitude to prescribe drugs off label for anyone they think may medically benefit, and many patients have found doctors — or, failing that, nurse practitioners or medi-spas — ready to certify that they would. Or some, like Allison, find it through a peddler not particular about a prescription or in the web’s dark morass.

To get hers, Allison calls up a Los Angeles–based provider she has never seen or met, sends over $625, and is shipped a monthly supply. What she calls Ozempic is not the brand-name product pre-packaged in a sky-blue injector pen by Novo Nordisk, the Danish pharmaceutical company that makes and markets the drug. She receives generic semaglutide, the active ingredient in the medication, and has to mix and prepare it for injection herself, which — since semaglutide is under patent by Novo Nordisk until 2032 in the U.S. — suggests her meds are likely coming from a compounding pharmacy or a vendor selling research-grade ingredients. The lower price is also a tell: Ozempic retails for about $900 a month if your insurance doesn’t cover it.

#long reads #*drugs #*alcohol #*eating disorder #*body image #*weight loss

17 notes · View notes

geraskier · 2 years

Text

oooooo ok i really enjoyed the talk dr. mcclung gave, and i had a chance to speak with him afterwards too. apparently he's been able to have topical genital testosterone cream prescribed for patients in the u.s. even if they are not pursuing bottom surgery.

he said that to his knowledge T cream for genitals is not covered by insurance even if future bottom surgery is planned. his T prescriptions are run through a particular compounding pharmacy that he knows and trusts.

#newt needs a text post tag #mcclung #dht cream #testosterone cream #bottom surgery #metoidioplasty #phalloplasty #hrt #trans stuff etc tag #uhhhh gimme a day or so to rewrite my notes i'll rb when i do that #edited for clarity

29 notes · View notes

mightyflamethrower · 2 months

Text

Billionaire Doomsday Prepping: What Is Zuckerberg Hiding?

75THE WELLNESS COMPANY (SPONSORED)

4 Jan 2024121

5:40

The following content is sponsored by The Wellness Company.

It’s not often that construction workers sign NDAs.

But every worker on Mark Zuckerberg’s $270 million doomsday bunker on a Hawaiian island has been asked to sign a non-disclosure agreement and swear secrecy. As reported by Wired:

That price for a private residence is unparalleled in the local construction industry—as is the level of secrecy and security. “The only other time you see that is when you’re doing secure military installations,’ says one local construction industry official affiliated with the site. ‘For a private project to have an NDA attached to it is very rare.”

The massive compound might as well be a military installation: the plans call for accommodations for at least 30 people, with food production, water storage, blast doors, advanced security systems, and a medical facility.

Zuck isn’t alone in this frightening trend for 2024.

Zuck, who made his Big Tech billions by collecting data on the interactions of almost every human on planet Earth, is not the only billionaire to be building an apocalypse shelter.

Peter Thiel’s attempt to build a giant bunker in New Zealand was rejected by the locals in 2022 due to its potential impact on the landscape. While there has been no solid proof, rumors are swirling that upwards of 15 other billionaires have been building advanced survival compounds, according to dataconomy.com.

When billionaires prep for the end of the world, we should pay attention.

No matter what’s coming in 2024, the most important thing you can do is be prepared ahead of time with food, ammo, gold, and medication: That’s where The Wellness Company’s Medical Emergency Kits come in.

The Wellness Company and their great doctors – like Dr. Peter McCullough, Dr. Drew, Dr. Harvey Risch, and Dr. Jim Thorp – are regularly in the media fighting warning Americans to take charge of their own health and wellness.

Dr. Thorp, one of the nation’s leading critics of the U.S. public health policies, believes that now – more than ever – people should be prepared for the next crisis:

We can’t rely on our crumbling healthcare system to have our backs in an emergency. I’ve strongly recommended “stockpiling” critical medications for years – like the meds found in our Medical Emergency Kits. Early intervention is KEY at the first sign of symptoms. Taking an active approach by being prepared for the next illness has helped my family tremendously.

The Wellness Company and their doctors are medical professionals that you can trust and their new Medical Emergency Kits are the gold standard when it comes to keeping you safe and healthy.

Have Ivermectin, Amoxicillin, and Z-Pak on hand.

Be ready for the next crisis. This medical emergency kit contains an assortment of life-saving medications – including antibiotics, antivirals, and antiparasitics. The Medical Emergency Kit includes a guidebook to aid in the safe use of these life-saving medications.

This kit is prescription-only – you can’t find it in any store or pharmacy. Order your kit at The Wellness Company and simply fill out a short questionnaire after purchase and a trusted Wellness Company doctor will confirm your suitability and issue your prescription Medical Emergency Kit.

The Wellness Company Medical Emergency Kit includes:

1 note · View note

tangledhearts1 · 1 year

Text

Decisions by CVS and Optum Panicked Thousands of Their Sickest Patients

Arthur Allen

NEW YORK — The fear started when a few patients saw their nurses and dietitians posting job searches on LinkedIn.

Word spread to Facebook groups, and patients started calling Coram CVS, a major U.S. supplier of the compounded IV nutrients on which they rely for survival. To their dismay, CVS Health confirmed the rumors on June 1: It was closing 36 of the 71 branches of its Coram home infusion business and laying off about 2,000 nurses, dietitians, pharmacists, and other employees.

Many of the patients left in the lurch have life-threatening digestive disorders that render them unable to eat or drink. They depend on parenteral nutrition, or PN — in which amino acids, sugars, fats, vitamins, and electrolytes are pumped, in most cases, through a specialized catheter directly into a large vein near the heart.

The day after CVS’ move, another big supplier, Optum Rx, announced its own consolidation. Suddenly, thousands would be without their highly complex, shortage-plagued, essential drugs and nutrients.

“With this kind of disruption, patients can’t get through on the phones. They panic,” said Cynthia Reddick, a senior nutritionist who was let go in the CVS restructuring.

“It was very difficult. Many emails, many phone calls, acting as a liaison between my doctor and the company,” said Elizabeth Fisher Smith, a 32-year-old public health instructor in New York City, whose Coram branch closed. A rare medical disorder has forced her to rely on PN for survival since 2017. “In the end, I got my supplies, but it added to my mental burden. And I’m someone who has worked in health care nearly my entire adult life.”

CVS had abandoned most of its less lucrative market in home parenteral nutrition, or HPN, and “acute care” drugs like IV antibiotics. Instead, it would focus on high-dollar, specialty intravenous medications like Remicade, which is used for arthritis and other autoimmune conditions.

Home and outpatient infusions are a growing business in the United States, as new drugs for chronic illness enable patients, health care providers, and insurers to bypass in-person treatment. Even the wellness industry is cashing in, with spa storefronts and home hydration services.

But while reimbursement for expensive new drugs has drawn the interest of big corporations and private equity, the industry is strained by a lack of nurses and pharmacists. And the less profitable parts of the business — as well as the vulnerable patients they serve — are at serious risk.

This includes the 30,000-plus Americans who rely for survival on parenteral nutrition, which has 72 ingredients. Among those patients are premature infants and post-surgery patients with digestive problems, and people with short or damaged bowels, often the result of genetic defects.

While some specialty infusion drugs are billed through pharmacy benefit managers that typically pay suppliers in a few weeks, medical plans that cover HPN, IV antibiotics, and some other infusion drugs can take 90 days to pay, said Dan Manchise, president of Mann Medical Consultants, a home care consulting company.

In the 2010s, CVS bought Coram, and Optum bought up smaller home infusion companies, both with the hope that consolidation and scale would offer more negotiating power with insurers and manufacturers, leading to a more stable market. But the level of patient care required was too high for them to make money, industry officials said.

“With the margins seen in the industry,” Manchise said, “if you’ve taken on expensive patients and you don’t get paid, you’re dead.”

In September, CVS announced its purchase of Signify Health, a high-tech company that sends out home health workers to evaluate billing rates for “high-priority” Medicare Advantage patients, according to an analyst’s report. In other words, as CVS shed one group of patients whose care yields low margins, it was spending $8 billion to seek more profitable ones.

CVS “pivots when necessary,” spokesperson Mike DeAngelis told KHN. “We decided to focus more resources on patients who receive infusion services for specialty medications” that “continue to see sustained growth.” Optum declined to discuss its move, but a spokesperson said the company was “steadfastly committed to serving the needs” of more than 2,000 HPN patients.

DeAngelis said CVS worked with its HPN patients to “seamlessly transition their care” to new companies.

However, several Coram patients interviewed about the transition indicated it was hardly smooth. Other HPN businesses were strained by the new demand for services, and frightening disruptions occurred.

Smith had to convince her new supplier that she still needed two IV pumps — one for HPN, the other for hydration. Without two, she’d rely partly on “gravity” infusion, in which the IV bag hangs from a pole that must move with the patient, making it impossible for her to keep her job.

“They just blatantly told her they weren’t giving her a pump because it was more expensive, she didn’t need it, and that’s why Coram went out of business,” Smith said.

Many patients who were hospitalized at the time of the switch — several inpatient stays a year are not unusual for HPN patients — had to remain in the hospital until they could find new suppliers. Such hospitalizations typically cost at least $3,000 a day.

“The biggest problem was getting people out of the hospital until other companies had ramped up,” said Dr. David Seres, a professor of medicine at the Institute of Human Nutrition at Columbia University Medical Center. Even over a few days, he said, “there was a lot of emotional hardship and fear over losing long-term relationships.”

To address HPN patients’ nutritional needs, a team of physicians, nurses, and dietitians must work with their supplier, Seres said. The companies conduct weekly bloodwork and adjust the contents of the HPN bags, all under sterile conditions because these patients are at risk of blood infections, which can be grave.

As for Coram, “it’s pretty obvious they had to trim down business that was not making money,” Reddick said, adding that it was noteworthy both Coram and Optum Rx “pivoted the same way to focus on higher-dollar, higher-reimbursement, high-margin populations.”

“I get it, from the business perspective,” Smith said. “At the same time, they left a lot of patients in a not great situation.”

***

Smith shares a postage-stamp Queens apartment with her husband, Matt; his enormous flight simulator (he’s an amateur pilot); cabinets and fridges full of medical supplies; and two large, friendly dogs, Caspian and Gretl. On a recent morning, she went about her routine: detaching the bag of milky IV fluid that had pumped all night through a central line implanted in her chest, flushing the line with saline, injecting medications into another saline bag, and then hooking it through a paperback-sized pump into her central line.

Smith has a connective tissue disorder called Ehlers-Danlos syndrome, which can cause many health problems. As a child, Smith had frequent issues such as a torn Achilles tendon and shoulder dislocations. In her 20s, while working as an EMT, she developed severe gut blockages and became progressively less able to digest food. In 2017, she went on HPN and takes nothing by mouth except for an occasional sip of liquid or bite of soft food, in hopes of preventing the total atrophy of her intestines. HPN enabled her to commute to George Washington University in Washington, D.C., where in 2020 she completed a master’s in public health.

On days when she teaches at LaGuardia Community College — she had 35 students this semester — Smith is up at 6 a.m. to tend to her medical care, leaves the house at 9:15 for class, comes home in the afternoon for a bag of IV hydration, then returns for a late afternoon or evening class. In the evening she gets more hydration, then hooks up the HPN bag for the night. On rare occasions she skips the HPN, “but then I regret it,” she said. The next day she’ll have headaches and feel dizzy, sometimes losing her train of thought in class.

Smith describes a “love-hate relationship” with HPN. She hates being dependent on it, the sour smell of the stuff when it spills, and the mountains of unrecyclable garbage from the 120 pounds of supplies couriered to her apartment weekly. She worries about blood clots and infections. She finds the smell of food disconcerting; Matt tries not to cook when she’s home. Other HPN patients speak of sudden cravings for pasta or Frosted Mini-Wheats.

Yet HPN “has given me my life back,” Smith said.

She is a zealous self-caretaker, but some dangers are beyond her control. IV feeding over time is associated with liver damage. The assemblage of HPN bags by compounding pharmacists is risky. If the ingredients aren’t mixed in the right order, they can crystallize and kill a patient, said Seres, Smith’s doctor.

He and other doctors would like to transition patients to food, but this isn’t always possible. Some eventually seek drastic treatments such as bowel lengthening or even transplants of the entire digestive tract.

“When they run out of options, they could die,” said Dr. Ryan Hurt, a Mayo Clinic physician and president of the American Society for Parenteral and Enteral Nutrition.

***

And then there are the shortages.

In 2017, Hurricane Maria crippled dozens of labs and factories making IV components in Puerto Rico; next came the covid-19 emergency, which shifted vital supplies to gravely ill hospital patients.

Prices for vital HPN ingredients can fluctuate unpredictably as companies making them come and go. For example, in recent years the cost of the sodium acetate used as an electrolyte in a bag of HPN ballooned from $2 to $25, then briefly to $300, said Michael Rigas, a co-founder of the home infusion pharmacy KabaFusion.

“There may be 50 different companies involved in producing everything in an HPN bag,” Rigas said. “They’re all doing their own thing — expanding, contracting, looking for ways to make money.” This leaves patients struggling to deal with various shortages from saline and IV bags to special tubing and vitamins.

“In the last five years I’ve seen more things out of stock or on shortage than the previous 35 years combined,” said Rigas.

The sudden retrenchment of CVS and Optum Rx made things worse. Another, infuriating source of worry: the steady rise of IV spas and concierge services, staffed by moonlighting or burned-out hospital nurses, offering IV vitamins and hydration to well-off people who enjoy the rush of infusions to relieve symptoms of a cold, morning sickness, a hangover, or just a case of the blahs.

In January, infusion professionals urged FDA Commissioner Robert Califf to examine spa and concierge services’ use of IV products as an “emerging contributing factor” to shortages.

The FDA, however, has little authority over IV spas. The Federal Trade Commission has cracked down on some spa operations — for unsubstantiated health claims rather than resource misuse.

Bracha Banayan’s concierge service, called IVDRIPS, started in 2017 in New York City and now employs 90 people, including 60 registered nurses, in four states, she said. They visit about 5,000 patrons each year, providing IV hydration and vitamins in sessions of an hour or two for up to $600 a visit. The goal is “to hydrate and be healthy” with a “boost that makes us feel better,” Banayan said.

Although experts don’t recommend IV hydration outside of medical settings, the market has exploded, Banayan said: “Every med spa is like, ‘We want to bring in IV services.’ Every single paramedic I know is opening an IV center.”

Matt Smith, Elizabeth’s husband, isn’t surprised. Educated as a lawyer, he is a paramedic who trains others at Columbia University Irving Medical Center. “You give someone a choice of go up to some rich person’s apartment and start an IV on them, or carry a 500-pound person living in squalor down from their apartment,” he said. “There’s one that’s going to be very hard on your body and one very easy on your body.”

The very existence of IV spa companies can feel like an insult.

“These people are using resources that are literally a matter of life or death to us,” Elizabeth Smith said.

Shortages in HPN supplies have caused serious health problems including organ failure, severe blisters, rashes, and brain damage.

For five months last year, Rylee Cornwell, 18 and living in Spokane, Washington, could rarely procure lipids for her HPN treatment. She grew dizzy or fainted when she tried to stand, so she mostly slept. Eventually she moved to Phoenix, where the Mayo Clinic has many Ehlers-Danlos patients and supplies are easier to access.

Mike Sherels was a University of Minnesota Gophers football coach when an allergic reaction caused him to lose most of his intestines. At times he’s had to rely on an ethanol solution that damages the ports on his central line, a potentially deadly problem “since you can only have so many central access sites put into your body during your life,” he said.

When Faith Johnson, a 22-year-old Las Vegas student, was unable to get IV multivitamins, she tried crushing vitamin pills and swallowing the powder, but couldn’t keep the substance down and became malnourished. She has been hospitalized five times this past year.

Dread stalks Matt Smith, who daily fears that Elizabeth will call to say she has a headache, which could mean a minor allergic or viral issue — or a bloodstream infection that will land her in the hospital.

Even more worrying, he said: “What happens if all these companies stop doing it? What is the alternative? I don’t know what the economics of HPN are. All I know is the stuff either comes or it doesn’t.”

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

USE OUR CONTENT

This story can be republished for free (details).

Read more here https://angelino.news

#LA News #Orange County News

3 notes · View notes

bhushans · 9 days

Text

Global Sphingolipids Market: A Deep Dive into Key Drivers and Trends

The global clot-busting drugs market is expected to have a significant increase in market value, reaching approximately USD 28.8 billion in 2022. By the end of 2032, the market is expected to have grown at a solid Compound Annual Growth Rate (CAGR) of 7.3%, propelling it to a valuation of USD 58.4 billion.

Among other thrombotic diseases, thrombolytics—drugs that break up blood clots—are crucial for the treatment of heart attacks, strokes, and pulmonary emboli. These drugs can improve patient outcomes and lower the risk that severe consequences in critical medical conditions will occur by dissolving blood clots and restoring blood flow to injured tissues.

Companies are creating new clot busting medications with fewer side effects and at a lower cost because customers aren’t receiving clot busting medicines as intended because of misconceptions and the treatments’ negative consequences. It is anticipated that this will greatly increase the acceptance and use of clot-busting drugs. Over the anticipated timeframe, increasing product releases and approvals are anticipated to fuel more market expansion.

Gain a Competitive Edge: Request Your Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-15689

Key Takeaways from Market Study

Anticoagulants are the leading segment as a product, and hold approximately 36.7% market share in 2021, due to the rise in chronic diseases, the development of anticoagulant medicines has become more molecularly and biologically advanced, and emerging nations are increasingly using novel oral anticoagulants.

Pulmonary Embolism are the leading segment by indication, and held about 31.2% market share in 2021, owing to the increasing number of cancer patients and patients who have a family history of cardiovascular issues.

Injectable category is the leading segment in route of administration of drugs by holding more than half of the global market share owed to growing need for tools like safety syringes, prefilled syringes, and auto-injectors for the prevention of needle stick injuries.

Hospital Pharmacy is the leading distribution channel as of 2021, withholding about one third of the global market share by value due to wide range of product availability, convenience and patients’ reliance on hospitals for treatments.

By region, North America is leading in the global clot busting drugs market with 32.4% of the revenue share on 2021 and is expected to continue to do so with a projected CAGR rate of 8.0% during the forecasted years.

“Rising initiatives to promote health benefits of clot busting drugs, as well as the increasing awareness about the prevention of heart attacks and strokes is set to propel the sales of clot busting drugs devices across the globe,” says an analyst of Future Market Insights.

Market Competition

The market for clot busting drugs is quite competitive due to the presence of numerous local or regional players. The companies are concentrating on implementing different business strategies, such as product launches, drug development, and geographic expansions. For Instance:

In Dec 2021, Janssen Pharmaceutical received U.S. FDA approval for its oral anticoagulant called XARELTO (rivaroxaban). The drug was approved for 2 indications for pediatric category which includes prophylaxis of DVT or deep vein thrombosis resulting in pulmonary embolism.

AstraZeneca’s Brilinta (ticagrelor) received FDA approval for its P2Y12 receptor antagonist, an oral, reversible drug that prevents platelet activation, in June 2020 to lower the risk of a stroke or a first heart attack in patients with high-risk of coronary artery disease (CAD).

Key Segments Covered in Clot Busting Drugs Industry Research

By Product:

Thrombolytic Drugs

Anti-Platelet Drugs

Anticoagulants

Others

By Indication:

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Others

By Route of Administration:

Oral

Injectable

By Distribution Channel:

Hospital Pharmacy

Drug Store

Online Pharmacy

Retail Pharmacy

By Region:

North America

Latin America

Europe

East Asia

South Asia

Oceania

Middle-East and Africa (MEA)

0 notes

visionresearchreport · 2 months

Text

According to Vision Research Reports, the U.S. compounding pharmacies market size was estimated at USD 5.79 billion in 2023 and it is expected to increase around USD 10.39 billion by 2033 with a CAGR of 6.02% from 2024 to 2033.

#healthcare #compounding #market research

0 notes

xtruss · 4 months

Text

Scientists Tested 3 Popular Bottled Water Brands For Nanoplastics Using New Tech, And Yikes

The Results Were Alarming—An Average of 240,000 Nanoplastics Per 1 Liter Bottle—But What Does It Mean For Our Health?

— Annie Reneau | February 02, 2024 | UpWorthy.Com

Suzy Hazelwood/Canva

Columbia University researchers tested bottled water for nanoplastics and found hundreds of thousands of them.

Evian, Fiji, Voss, SmartWater, Aquafina, Dasani—it's impressive how many brands we have for something humans have been consuming for millennia. Despite years of studies showing that bottled water is no safer to drink than tap water, Americans are more consuming more bottled water than ever, to the tune of billions of dollars in bottled water sales.

People cite convenience and taste in addition to perceived safety for reasons they prefer bottle to tap, but the fear factor surrounding tap water is still a driving force. It doesn't help when emergencies like floods cause tap water contamination or when investigations reveal issues with lead pipes in some communities, but municipal water supplies are tested regularly, and in the vast majority of the U.S., you can safely grab a glass of water from a tap.

And now, a new study on nanoplastics found in three popular bottled water brands is throwing more data into the bottled vs. tap water choice.

Researchers from Columbia University used a new laser-guided technology to detect nanoplastics that had previously evaded detection due to their miniscule size. The new technology can detect, count and analyze and chemical structure of nanoparticles, and they found seven different major types of plastic: polyamide, polypropylene, polyethylene, polymethyl methacrylate, polyvinyl chloride, polystyrene, and polyethylene terephthalate.

In contrast to a 2018 study that found around 300 plastic particles in an average liter of bottled water, the study published in the journal Proceedings of the National Academy of Sciences in January of 2024 found 240,000 nanoplastic particles per liter bottle on average between the three brands studied. (The name of the brands were not indicated in the study.)

As opposed to microplastics, nanoplastics are too small to be seen by microscope. Their size is exactly why experts are concerned about them, as they are small enough to invade human cells and potentially disrupt cellular processes.

“Micro and nanoplastics have been found in the human placenta at this point. They’ve been found in human lung tissues. They’ve been found in human feces; they’ve been found in human blood,” study coauthor Phoebe Stapleton, associate professor of pharmacology and toxicology at Rutgers University’s Ernest Mario School of Pharmacy told CNN Health,

We know that nanoplastics are making their way into our bodies. We just don't have enough research yet on what that means for our health, and we still have more questions than answers. How many nanoplastics does it take to do damage and/or cause disease? What kinds of damage or disease might they cause? Is whatever effect they might have cumulative? We simply don't have answers to these questions yet.

That's not to say there's no cause for concern. We do know that certain levels of microplastic exposure have been shown to adversely affect the viability of cells. Nanoplastics are even smaller—does that mean they are more likely to cause cellular damage? Science is still working that out.

According to Dr. Sara Benedé of the Spanish National Research Council’s Institute of Food Science Research, it's not just the plastics themselves that might cause damage, but what they may bring along with them. “[Microparticles and nanoparticles] have the ability to bind all kinds of compounds when they come into contact with fluids, thus acting as carriers of all kinds of substances including environmental pollutants, toxins, antibiotics, or microorganisms,” Dr. Benedé told Medical News Today.

Where is this plastic in water coming from? This study focused on bottled water, which is almost always packaged in plastic. The filters used to filter the water before bottling are also frequently made from plastic.

Is it possible that some of these nanoplastics were already present in the water from their original sources? Again, research is always evolving on this front, but microplastics have been detected in lakes, streams and other freshwater sources, so it's not a big stretch to imagine that nanoplastics may be making their way into freshwater ecosystems as well. However, microplastics are found at much higher levels in bottled water than tap water, so it's also not a stretch to assume that most of the nanoplastics are likely coming from the bottling process and packaging rather than from freshwater sources.

The reality is, though, we simply don't know yet.

“Based on other studies we expected most of the microplastics in bottled water would come from leakage of the plastic bottle itself, which is typically made of PET (polyethylene terephthalate) plastic,” lead author Naixin Qian, a doctoral student in chemistry at Columbia University, told CNN Health. “However, we found there’s actually many diverse types of plastics in a bottle of water, and that different plastic types have different size distributions. The PET particles were larger, while others were down to 200 nanometers, which is much, much smaller.”

We need to drink water, and we need to drink safe water. At this point, we have plenty of environmental reasons for avoiding bottled water unless absolutely necessary and opting for tap water instead. Even if there's still more research to be done, the presence of hundreds of thousands of nanoplastics in bottled water might just be another reason to make the switch.

0 notes

creative-news-alert · 4 months

Text

Netherlands Compounding Pharmacies is estimated to Witness High Growth owing to increasing demand for customized medicines

Compounding pharmacies in Netherlands have created unique opportunities for pharmacists to combine, mix, or alter ingredients to create customized medicines for specific medical conditions of individual patients. Compounded medications are prescribed when an FDA-approved product is unavailable or when a health care provider decides that an alternate ingredient, dosage form or strength would better treat a patient's medical condition. For example, if a patient is allergic to an ingredient in an FDA-approved medication, a compounded version can be made without the ingredient they are allergic to.

The Netherlands Compounding Pharmacies Market is estimated to be valued at US$ 599.62 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The growing demand for customized medicines due to increase in prevalence of allergies and chronic conditions are mainly driving the Netherlands Compounding Pharmacies market. Compounded medications allow formulations tailored to meet specific needs of patients who may be allergic to inactive ingredients in FDA-approved medications, cannot consume certain product formats like a pill-based solution, or need a specific dosage unattainable through commercially available products. According to the U.S. Food and Drug Administration (FDA), in 2020, approximately 50% of adverse drug reactions reported were caused by inactive ingredients that some patients were allergic to.Compounded medications avoid exposure to these allergens while still providing treatment. Moreover, compounded drugs offer solutions for chronic diseases and complex medical conditions that commercially available products cannot adequately treat. This drives the demand for Netherlands Compounding Pharmacies. SWOT Analysis Strength: The Netherlands compounding pharmacies market share has highly skilled pharmacists and stringent regulatory guidelines. Compounding pharmacies in Netherlands provide tailored medications to meet specific needs of patients. Customized medications ensure better treatment outcomes. Weakness: Shortage of raw materials and API supplies can hamper compounding activities. High operation and production costs associated with small batch sizes pose financial challenges. Opportunity: Growing geriatric population and rising prevalence of chronic diseases will drive demand for compounded formulations. Advancements in 3D printing and robotics provide opportunities to streamline production processes. Threats: Stringent regulatory environment may increase compliance costs. Intense competition from generic drug manufacturers poses pricing pressures. Supply chain disruptions due to global health crisis threaten timely availability of medicines. Key Takeaways The Netherlands compounding pharmacies market is expected to witness high growth. The Netherlands Compounding Pharmacies Market is estimated to be valued at US$ 599.62 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 to 2031. The Netherlands compounding pharmacies market is dominated by Western Europe region. Factors such as high healthcare expenditure, favorable reimbursement policies, and growing pharmaceutical industry contribute to the large market share. The availability of advanced healthcare facilities and skilled pharmacy professionals also support market growth in the region. Key players related content comprises Key players operating in the Netherlands compounding pharmacies market are GE Healthcare, Invacare Corporation, Inogen, IUC Medical (Smiths Medical), HERSILL S.L., Fisher & Paykel Healthcare Limited, Philips Respironics, Inc., DeVilbiss Healthcare, Tecno-Gaz Industries, Allied Healthcare Products, Inc., Teleflex Incorporated, Chart Industries, ResMed, and Drägerwerk AG & Co. KGaA. These players are focused on product innovation and geography expansion strategies to strengthen their market position.Get more insights on this topic:https://www.newswirestats.com/netherlands-compounding-pharmacies-market-size-and-outlook/

#Netherlands Compounding Pharmacies #Netherlands Compounding Pharmacies Market #Netherlands Compounding Pharmacies Market size #Netherlands Compounding Pharmacies Market share #Coherent Market Insights

0 notes

blog-site-for-market-research · 4 months

Text

Automatic Pill Dispenser Market Size, Share & Regional Forecast, 2023-2032

Brief Overview

Automatic pill dispensers are systems designed to dispense medicines without the need for supervision. This would be beneficial to the elderly and patients unable to stand in long queues. It can manage complex medication regimes and reduce waiting times at pharmacies. In addition, the presence of these machines in retirement communities and assisted living facilities can reduce the shift times of nurses. It can also lower complexities in distribution of medicines. The global automatic pill dispenser market report by Market Research Future (MRFR) takes a look at the various factors surrounding the industry and makes projections for the period of 2023 to 2032 (forecast period).

Market Outlook

The Automatic Pill Dispenser Market Size was evaluated at USD 3 billion in 2021 and is expected to rise from USD 3.25 billion in 2022 to USD 6.78 billion by 2032, with a compound annual growth rate (CAGR) of 8.5% over the forecast period (2023-2032).

The growing numbers of the geriatric population is one of the primary drivers of the market. The elderly find it difficult to adhere to medication refills and automated pill dispensers can lend its assistance in this regard. According to the World Health Organization (WHO), the population of the elderly can magnify to 22% of the global population by 2050.

Other factors driving market growth include adoption of pill dispensers in home care centers, rise in regulatory approvals of drugs, advances in automatic pill dispensing systems, and awareness of timely intake of medications. The use of these pill dispensing systems to reduce the rounds of doctors and nurses as well as assist patients in attaining their daily nutrient intake can bode well for the global automatic pill dispenser market.

But the high costs of these systems can hamper market growth.

Segmentation

The global automatic pill dispenser market is segmented based on type and end user.

The global automatic pill dispenser industry is segmented by type into centralized automated dispensing system and decentralized automated dispensing system. The centralized automated dispensing system is further segmented into robotic automated dispensing systems and carousels. Furthermore, decentralized automated dispensing systems are segmented into automated unit dose dispensing system, pharmacy-based automated dispensing system, and ward-based automated dispensing system.

Based on end user, the market is segmented into home healthcare, hospital pharmacy, and retail pharmacy.

Regional Analysis

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).

The Americas had dominated the market owing to the large geriatric population in the region. The allocation of a large amount of healthcare expenditure for assisted living facilities and hospitals for dispensing medicines to the elderly can drive the market demand. According to the World Health Organization, the U.S. geriatric population can account for more than 20% of the total population in the country. High prevalence of chronic diseases such as cardiovascular diseases (CVD), diabetes, cancer, and others as well as efforts by pill dispensing manufacturers to improve the system for making it accessible for the elderly can augur favorably for the global automatic pill dispenser market research.

Europe had assumed the second position in the global owing to receiving funds for research and development and technological advances in these systems. Adherence to medications is the primary driver of the regional market. According to the National Health Service (NHS), close to USD 124 million of drugs had to be returned due to its non-utilization.

Competitive Outlook

Becton, Dickinson and Company, Yuyama Co.Ltd., McKesson Corporation, Omnicell Inc., Cerner Corporation, Swisslog Holdings AG, Capsa Healthcare, Talyst, Inc., ScriptPro LLC, and Baxter International Inc. are key players of the global automatic pill dispenser market.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: [email protected]

Website: https://www.marketresearchfuture.com

#Automatic Pill Dispenser Market #Automatic Pill Dispenser Market Size #Automatic Pill Dispenser Market Share #Automatic Pill Dispenser Market Trends #Automatic Pill Dispenser Market Growth #Automatic Pill Dispenser Market Analysis #Automatic Pill Dispenser Market Report #Automatic Pill Dispenser Market Outlook

0 notes